Pamidronate--a promising new candidate for the management of spondyloarthropathy.
Bisphosphonate group of agents are known for their anti-bone resorptive properties. However, recently their anti-inflammatory and anti-arthritis properties have come to light. Clinical trials of their use in spondyloarthropathy are showing promising results, especially in patients with shorter disease duration. The adverse event profile is mainly limited to postinfusion arthralgia, myalgia and fever. The concept of pamidronate in spondyloarthropathy management should be evaluated further in light of these clinical studies and could have a major impact on our resource-restricted setting.
Akerkar
S M
SM
Department of Medicine, Seth GS and KEM Hospital, Parel, Mumbai, India. shashank77_2000@yahoo.com
Bichile
L S
LS
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D000077268:Pamidronate; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate